Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Add a description, image, and links to the javascript-2 topic page so that developers can more easily learn about it.

Chinese tech giant Baidu launched its new flagship AI model, ERNIE 5.0, in Beijing on Thursday. The company unveiled the system at its Baidu World 2025 event. It is built to handle text, images, audio ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based ...

Abstract: A new algebraic approach to approximation of correlation matrices of discrete signals based on a special family of square matrices with sparse circulant alternation of elements is developed.

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...

Abstract: To enhance the 2-D resolution for spaceborne-groundbase bistatic inverse synthetic aperture radar (Bi-ISAR) imaging of aircraft targets, obtaining a large rotational angle between the target ...

Tree recursion is a technique used to traverse a tree-like data structure by recursively visiting each node and its children. It’s widely used in computer science, particularly in algorithms that ...

The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc.